New flu vaccine shows promise in south korean trial

NCT ID NCT05144945

Completed ⭐️ VACCINE ⭐️ Sponsor: Sanofi Pasteur, a Sanofi Company Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 3 trial tested a new recombinant flu vaccine (RIV4) against a standard inactivated flu vaccine (IIV4) in 301 healthy adults aged 18 and older in South Korea. The study measured antibody levels and safety over 29 days. The goal was to see if the new vaccine triggers a stronger immune response with similar safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Quadrivalent Recombinant Influenza Vaccine (RIV4)
What this could lead to: If successful, this could offer a more effective or equally protective flu vaccine option for adults, especially those 50 and older.
What could go wrong: This is a completed phase 3 trial, but results may not apply to all populations or flu seasons. The new vaccine may not prove superior to the existing one.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLUENZA (HEALTHY VOLUNTEERS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

influenza prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFLUENZA (HEALTHY VOLUNTEERS)

Contacts and locations

Locations

Investigational Site Number :4100001

Seoul, Seoul-teukbyeolsi, 152-703, South Korea
Investigational Site Number :4100002

Seoul, 07441, South Korea
Investigational Site Number :4100003

Ansan-si, Gyeonggi-do, 15355, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.